According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...
Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Cyberknife Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The CyberKnife market is redefining precision ...
How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Humphrey traveled from Michigan to Chicago to seek a second opinion at Northwestern Medicine in May 2024. A bronchoscopy ...
Lung cancer remains the leading cause of cancer death, but advances in screening, surgery and personalized treatment are ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in ...
News-Medical.Net on MSN
Innovative CRISPR strategy resensitizes lung cancer to treatment
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback